Johnson & Johnson $JNJ Shares Acquired by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. grew its stake in Johnson & Johnson (NYSE:JNJ) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 915,750 shares of the company’s stock after buying an additional 45,330 shares during the period. Johnson & Johnson accounts for 0.7% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 20th largest holding. Resona Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $139,833,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the 1st quarter worth $218,000. Smart Money Group LLC boosted its stake in Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares during the period. Financial Counselors Inc. boosted its stake in Johnson & Johnson by 8.3% during the 1st quarter. Financial Counselors Inc. now owns 182,888 shares of the company’s stock worth $30,330,000 after purchasing an additional 13,957 shares during the period. Finally, Brass Tax Wealth Management Inc. boosted its stake in Johnson & Johnson by 5.6% during the 1st quarter. Brass Tax Wealth Management Inc. now owns 4,343 shares of the company’s stock worth $720,000 after purchasing an additional 230 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

Shares of Johnson & Johnson stock opened at $186.23 on Thursday. The company has a market cap of $448.68 billion, a P/E ratio of 17.98, a PEG ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The firm has a fifty day moving average of $183.83 and a two-hundred day moving average of $168.29.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Citigroup increased their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. UBS Group upped their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.